UBS Group
PBYI icon

UBS Group’s Puma Biotechnology PBYI Stock Holding History

UBS Group’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-10,400
Closed -$2.46M – 8745
2015
Q1 		$2.46M Buy
10,400
+9,800
+1,633% +$2.09M ﹤0.01% 2741
2014
Q4 		$114K Buy
+600
New +$133K ﹤0.01% 5572

Other funds holding PBYI

ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

UBS Group's PBYI Position: Q2 2026 in Review

UBS Group increased its Puma Biotechnology (PBYI) stake by 19% in Q2 2026, buying an estimated $751K and bringing the position to 636,761 shares worth $5.16M. The position accounts for ﹤0.01% of the portfolio, ranked #4126.

UBS Group first reported a position in PBYI in Q4 2014 and has held it in 47 quarters since. The position peaked at $28.4M in Q1 2015. 161 funds tracked by Wall St. Rank hold PBYI as of Q2 2026.

  • UBS Group held 636,761 shares of Puma Biotechnology worth $5.16M as of Q2 2026.
  • UBS Group bought 102,534 Puma Biotechnology shares in Q2 2026, an estimated $751K.
  • Puma Biotechnology made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #4126 holding.
  • UBS Group first reported a position in Puma Biotechnology in Q4 2014 and has held it in 47 quarters since.
  • UBS Group's Puma Biotechnology position peaked at $28.4M in Q1 2015.
  • 161 funds tracked by Wall St. Rank held Puma Biotechnology as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.